Keyword: University College London
Sophiris will push its lead drug topsalysin into phase 3 testing, though a second dose showed no additional benefit in its prostate cancer trial.
Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.
The initiative is seeking to build on the progress of British cell and gene therapy university spinouts such as Autolus and Orchard Therapeutics.
Syncona committed £85 million to Freeline, maintaining a big stake in a biotech that aims to redefine treatment of hemophilia B and Fabry disease.
The transatlantic biotech is initially targeting inherited retinal diseases with therapies designed to halt vision loss.
The aim is to apply Synpromics’ synthetic promoter expertise to the development of gene therapies against diseases affecting the blood.
The pact will see UCL work with Synpromics on synthetic gene promoters that enable highly specific gene therapies.
An approved diabetes drug may change the progression of Parkinson's disease rather than just treating symptoms while the disease worsens.
Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor cell therapy.
Cell Medica has raised £60 million ($74 million) to expand its clinical pipeline of cancer cellular immunotherapies.